Last reviewed · How we verify
NCT05617469
DLCS for Predicting Neoadjuvant Chemotherapy Response
trial testing develop and visualized a radio-clinical signatures from pretreatment oversampled CT images in Gastric Cancer in 1,100 participants. Status unknown.
30 January 2023
Quick facts
| Lead sponsor | Zhejiang Cancer Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,100 |
| Start date | 1 July 2022 |
| Primary completion | 30 January 2023 |
| Estimated completion | 31 July 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- develop and visualized a radio-clinical signatures from pretreatment oversampled CT images
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- CT Images — all drugs for CT Images →
- Deep Learning — all drugs for Deep Learning →
- Neoadjuvant Chemotherapy — all drugs for Neoadjuvant Chemotherapy →
Sponsor
Zhejiang Cancer Hospital
Who can join
Adults 18 to 80, any sex, with Gastric Cancer or CT Images. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The early noninvasive screening of patients suitable for neoadjuvant chemotherapy (NCT) is essential for personalized treatment in locally advanced gastric cancer (LAGC). The aim of this study was to develop and visualized a radio-clinical biomarker from pretreatment oversampled CT images to predict the response and prognosis to NCT in LAGC patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Deep learning radio-clinical signatures for predicting neoadjuvant chemotherapy response and prognosis from pretreatment CT images of locally advanced gastric cancer patients.
Hu C, Chen W, Li F, Zhang Y, et al · · 2023 · cited 33× · PMID 37132183 · DOI 10.1097/js9.0000000000000432 -
Development and validation of a deep learning model for predicting gastric cancer recurrence based on CT imaging: a multicenter study.
Cao M, Hu C, Li F, He J, et al · · 2024 · cited 7× · PMID 38896865 · DOI 10.1097/js9.0000000000001627
Verify or expand the search:
- PubMed search for NCT05617469
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Zhejiang Cancer Hospital trials
Trials by the same sponsor.
- NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
- NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
- NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05617469 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
- Last refreshed: 15 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05617469.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing